Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Sonpavde, Guru
Bhor, Menaka
Hennessy, Daniel
Bhowmik, Debajyoti
Shen, Liji
Schnadig, Ian D.
机构：
[1] UAB Comprehens Canc Ctr, Birmingham, AL USA
[2] McKesson Specialty Hlth, The Woodlands, TX USA
[3] US Oncol Network, The Woodlands, TX USA
[4] Sanofi Aventis, Bridgewater, NJ USA
[5] Compass Oncol, Portland, OR USA
[6] US Oncol Network, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)
    Sunil Parimi
    Misha Eliasziw
    Scott North
    Marc Trudeau
    Eric Winquist
    Kim N. Chi
    Dean Ruether
    Tina Cheng
    Bernhard J. Eigl
    Investigational New Drugs, 2016, 34 : 771 - 776
  • [22] Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Russell, Carly
    Small, Eric J.
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) : 66 - 73
  • [23] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Jensen, A.
    Karunaratna, N.
    Wong, S.
    Shapiro, J.
    Weickhardt, A.
    Spain, L.
    Azad, A. A.
    Kwan, E.
    Muthusamy, A.
    Torres, J.
    Parente, P.
    Francis, P.
    Parnis, F. X.
    Goh, J.
    Gibbs, P.
    Tran, B.
    Anton, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1329 - S1330
  • [24] Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
    Pond, Gregory Russell
    Sonpavde, Guru
    Fizazi, Karim
    De Bono, Johann S.
    Basch, Ethan M.
    Scher, Howard I.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Zukotynski, Katherine A.
    Jadvar, Hossein
    Cho, Steve Y.
    Kim, Chun Ki
    Cline, Kathryn
    Emmenegger, Urban
    Hotte, Sebastien J.
    Pond, Gregory Russell
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [29] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [30] Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
    Thoman, Maxton E.
    Salari, Keyan
    EUROPEAN UROLOGY, 2022, 82 (01) : 31 - 33
12345